Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.
能量平衡與肥胖:胰高血糖素樣肽-1 受體激動劑的新興角色。
Curr Opin Clin Nutr Metab Care 2024-08-16
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.
GLP-1 受體激動劑用於肥胖治療:作為一種有前途的方法。
Front Endocrinol (Lausanne) 2023-11-06
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
GLP-1激動劑在肥胖症中的新興角色:隨機對照試驗的全面回顧。
Int J Mol Sci 2023-07-18
Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
使用結合葡萄糖樣肽1受體的藥物治療肥胖:目前情況如何?
Expert Opin Pharmacother 2024-03-27
Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
生活方式和胰高血糖素樣肽-1受體激動劑在肥胖症、2型糖尿病和脂肪肝疾病中減重的作用。
Aliment Pharmacol Ther 2024-05-30
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19
Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.
非糖尿病患者使用胰高血糖素樣肽-1 (GLP-1) 受體激動劑進行減重管理的療效。
Cureus 2024-08-21
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
針對肥胖的胰高血糖素樣受體-1激動劑:體重減輕結果、耐受性、副作用及風險。
Obes Pillars 2024-09-17